   
Current Version Dat e: 24OCT2019  IRBNet #:  1000376  
Previous Version Date: 05SEP  2019  Page 1 of 46 
Research Study protocol template version date 11/3/[ADDRESS_693156].   
Orlando, FL [ZIP_CODE] 
[PHONE_11050] 
 
 
  
   
Current Version Dat e: 24OCT2019  IRBNet #:  1000376  
Previous Version Date: 05SEP  2019  Page 2 of 46 
Research Study protocol template version date 11/3/[ADDRESS_693157] OF ABBREVIATIONS  ......................................................................................................... 6  
INTRODUCTION  .......................................................................................................................... 8  
BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE  ....................................... 8  
STUDY OBJECTIVES  ................................................................................................................... 9  
STUDY DESIGN .......................................................................................................................... 11  
Research Design  ........................................................................................................................ 11  
Study Agent, Device, and/or Intervention Description ............................................................. 13  
Study Site(s)/Location(s) and Number of Subjects  .................................................................. 13  
Multi -Site Research Logistics/Communication Plan  ................................................................ [ADDRESS_693158] SELECTION  ............................................................................................................... 14  
Vulnerable Populations  ............................................................................................................. 14  
Inclusion Criteria  ...................................................................................................................... 14  
Exclusion Criteria  ..................................................................................................................... 15  
RESOURCES AVAILABLE  ........................................................................................................ 18  
Site Initiation/Study Specific Training  ..................................................................................... [ADDRESS_693159] Recruitment and Screening  .......................................................................................... 18  
Consent Process  ........................................................................................................................ 18  
Non-English Speaking Subjects ................................................................................................ 18  
Subjects who are Not Yet Adults (Infants, Children, Teenagers) ............................................. 18  
Cognitively Impaired Adults  ..................................................................................................... 18  
Documentation of Informed Consent Process .......................................................................... 19  
Waiver of Written Documentation of Consent or Waiver of Consent ...................................... 19  
Prohibitions and Restrictions .................................................................................................... 19  
Randomization .......................................................................................................................... 19  
STUD Y VISITS  ........................................................................................................................ 19  
Screening Visit 1 (SV1)  ........................................................................................................ 19  
   
Current Version Dat e: 24OCT2019  IRBNet #:  1000376  
Previous Version Date: 05SEP  2019  Page 3 of 46 
Research Study protocol template version date 11/3/2016  
 Screening Visi t 2 (SV2)  ........................................................................................................ 20  
Baseline Visit 1 (BLV1)  ....................................................................................................... 20  
Baseline Visit 2 (BLV2)  ....................................................................................................... 21  
Surgery (V3) – Day [ADDRESS_693160]-Surgery Visits  (V4) – Day 42 ±7 days (6 weeks) .................................................... 22  
(V5) – Day 84 ±7 days (12 weeks) ....................................................................................... 22  
(V6) – Day 182 ±14 days (26 weeks) ................................................................................... 22  
(V7) – Day 364 ±14 days (52 weeks) ................................................................................... 22  
DETAILED ANALYTICAL/CLINICAL PROCEDURES  ..................................................... 22  
Physical Examination and Medical History  .......................................................................... 22  
Drug, Alcohol, Tobacco Screen and AUDIT Questionnaire ................................................ 22  
Height, Body Weight, BMI Calculation ............................................................................... 22  
Vital Sign Measurements  ...................................................................................................... 22  
Screening Laboratory Assessments  ...................................................................................... 23  
Circulating Biomarkers  ......................................................................................................... 23  
Magnetic Resonance Imaging and Spectroscopy (MRI) ...................................................... 24  
FibroScan® ............................................................................................................................ [ADDRESS_693161] (HepQuant SHUNT Dual Cholate Liver Diagnostic Kit)  25 
Liver Biopsy.......................................................................................................................... 26  
STUDY DURATION  ............................................................................................................... 26  
MATERIALS OF HUMAN ORIGIN:  COLLECTION, PREPARATION, HANDLING 
AND SHIPPI[INVESTIGATOR_1645]  ....................................................................................................................... 27  
STUDY OUTCOME MEASURES (ENDPOINTS)  .................................................................... 28  
DATA MANAGEMENT AND QUALITY PLAN  ...................................................................... 28  
Data De -identification  ............................................................................................................... 28  
Data Confidentia lity, Storage, and Retention ........................................................................... 28  
Data Quality  .............................................................................................................................. 29  
Data Sharing (Outside of AdventHealth)  .................................................................................. 29  
SAMPLE SIZE DETERMINATION  ........................................................................................... 30  
STATISTICAL ANALYSIS PLAN  ............................................................................................. 30  
Summary Analyses ................................................................................................................... 30  
Analysis of PDFF and MRE ..................................................................................................... 31  
Multiplicity  ............................................................................................................................... 31  
Missing Data ............................................................................................................................. 31  
Analysis Populations ................................................................................................................. 31  
   
Current Version Dat e: 24OCT2019  IRBNet #:  1000376  
Previous Version Date: 05SEP  2019  Page 4 of 46 
Research Study protocol template version date 11/3/2016  
 POTENTIAL RISKS AND BENEFITS ....................................................................................... 32  
POTENTIAL BENEFITS ......................................................................................................... 32  
POTENTIAL RISKS  ................................................................................................................ 32  
Intravenous Lines/Blood Draws (e.g., Laboratory Samples) ................................................ 32  
Magnetic Resonance Imaging (MRI) and Spectroscopy  ...................................................... 32  
FibroScan® ............................................................................................................................ [ADDRESS_693162] (HepQuant SHUNT Liver Diagnostic Kit)  ..................... [ADDRESS_693163] (DSMB) or Equivalent ..................................................... [ADDRESS_693164] ( AUDIT) 
QUESTIONNAIRE  ...................................................................................................................... 45  
APPENDIX C. Liver Disease Score  ............................................................................................. 46  
   
Current Version Dat e: 24OCT2019  IRBNet #:  1000376  
Previous Version Date: 05SEP  2019  Page 5 of 46 
Research Study protocol template version date 11/3/[ADDRESS_693165] OF TABLES  
Table 1: Study Objectives and Endpoints ....................................................................................... [ADDRESS_693166] Eligibility  ............................................................................ 17 
 
   
Current Version Dat e: 24OCT2019  IRBNet #:  1000376  
Previous Version Date: 05SEP  2019  Page 6 of 46 
Research Study protocol template version date 11/3/[ADDRESS_693167]  
BMI  body mass index 
CAP  College of American Pathologists  
CAP™  Controlled Attenuation Parameter  
CBC complete blood count  
CJD Creutzfeldt -Jakob disease  
CMP  comprehensive metabolic panel  
CSR clinical study report  
DNA  deoxyribonucleic acid  
DSI Disease Severity Index derived from HepQuant SHUNT Dual Cholate Liver Diagnostic 
Kit 
DUA  Data Use Agreement  
d4-cholate  Cholic Acid -2,2,4,[ADDRESS_693168]  
IV intravenous  
LC-MS liquid chromatography- mass spectrometry  
   
Current Version Dat e: 24OCT2019  IRBNet #:  1000376  
Previous Version Date: 05SEP  2019  Page 7 of 46 
Research Study protocol template version date 11/3/[ADDRESS_693169] operating procedure  
SSP study specific procedure  
TRI-MD Translational Research Institute for Metabolism and Diabetes  
TSH thyroid stimulating hormone  
T4 thyroxine  
US [LOCATION_002]  
vCJD  variant Creutzfeldt -Jakob disease  
VCTE™  Vibration -Controlled Transient Elastography  
WI work instruction  
13C-cholate  Cholic Acid -24-13C 
β-hCG  beta subunit human chorionic gonadotropin  
  
   
Current Version Dat e: 24OCT2019  IRBNet #:  1000376  
Previous Version Date: 05SEP  2019  Page 8 of 46 
Research Study protocol template version date 11/3/2016  
 INTRODUCTION  
This document is a protocol for a human research study to evaluate imaging, circulating 
and microbiome  biomarkers of liver pathology in patients with non- alcoholic fatty liver disease 
(NAFLD)/non -alcoholic steatohepatitis (NASH).  The descr ibed study will be conducted 
in compliance with the protocol, Good Clinical Practices (GCP) International Council 
on Harmonis ation ( ICH) Guidelines (E6) for GCP standards as adopted by [CONTACT_33438] (FDA) and associated Federal regulations, and all applicable institutional research requirements.    
BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE  
The rise in prevalence of obesity across the U nited States (US) is accompanied by a host of 
cardiometabolic comorbidities, including NAFLD, which is now the most common cause of chronic liver disease in industrialized nations ( Ahmed 2010, Loomba 2013).  Indeed, NAFLD  
affects  approximately 20 –30% of normal weight individuals and 57–98% of obese individuals  
depending on population and diagnostic modality ( Vernon 2011).  Within the spectrum of 
NAFLD phenotypes, NASH is a condition that is distinguished from simple steatosis in that it includes necroinflammatory changes in addition to steatosis.  NASH is a burgeoning liver disease (estimated prevalence is 3 –5% of the US population) for which no approved therapeutic 
treatment currently exists  (Sanyal 2015).  
Approximately 25% of those diagnosed with NAFLD meet the histopathologic criteria for NASH ( Cohen 2011), which unlike the clinically benign condition of simple steatosis, poses 
a higher risk of progression to cirrhosis and development of hepatocellular carcinoma (HCC).  A major gap in the field is the inability to identify those who are at risk for progression from benign NAFLD to severe stages of NASH such as fibrosis, cirrhosis, and HCC.   
With treatment of NAFLD/NASH being a major public health objective, several promising therapi[INVESTIGATOR_533772].  However, one of the primary  challenges 
hindering development of treatments for NAFLD/NASH is the lack of non- invasive tools 
to accurately diagnose and  stage the disease.  Currently, most clinical  trials examining chronic 
liver disease rely heavily on histologic evaluation of a liver biopsy sample. T his diagnostic assay  
is associated with  a number of drawbacks.  In addition to risk of complications associated with 
the invasive nature of the biopsy procedure, the limited volume of tissue collected by [CONTACT_533791], while interpretation and scoring of the histology itself is a somewhat subjective process that can introduce variability to the assessment  (Raitziu  2005).  Therefore , 
there is a recognized need within the field to develop a non- invasive alternative to the liver 
biopsy for diagnosing and staging NAFLD/NASH.  Such a development would enable the design of clinical trials to assess efficacy of prospective compoun ds to treat NASH without the need 
for liver biopsies, thereby [CONTACT_533792] [ADDRESS_693170] been found to sufficiently correlate with stages of disease progression or NASH diagnosis to substitute for liver biopsy  in either the clinical care of patients or selection of 
patient s for clinical trials  (Alkhouri 2012, Papagianni 2015, Renelus 2016).  Among these 
methodologies, medical imaging approaches have garnered signi ficant interest within the 
   
Current Version Dat e: 24OCT2019  IRBNet #:  1000376  
Previous Version Date: 05SEP  2019  Page 9 of 46 
Research Study protocol template version date 11/3/2016  
 NAFLD research community given their potential to directly probe the extent of different 
pathophysiologic mechanisms within the liver itself ( Dulai 2016, Hashemi 2016).   
Over  the course of this study, longitudinal assessments of subjects with NASH will be performed 
using non- invasive imaging ( FibroScan® and magnetic resonance imaging [ MRI ] methods) to 
evaluate the effects of bariatric su rgery on the liver and on extra  hepatic depots of adipose tissue.  
A battery of circulating, functional, and microbiome -based assays will also be employed  to 
evaluate physiologic changes that occur in response to bar iatric surgery  (OWLiver Care analysis 
to discriminate between NA FLD and  healthy liver;  OWLiver Care analysis to discriminate 
between NASH and simpl e steatosis;  Nordic Bioscience panel to interrogate fibrogenic activity ; 
HepQuant SHUNT Dual Cholate Liver Diagnostic Kit test to monitor the effect of bariatric surgery on liver function; and stool sample  assays of the gut microbiome  to assess the effect of 
bariatric surgery on the composition, functionality, and metabolites of the microbiota ) (see the 
Research Design  section for detailed information and background on these procedures and 
assessments ).   
A population of patients undergoing standard of care bariatric surgery has been chosen because of the known effect of bariatric surgery on NASH.  Roux- en-Y gastric by[CONTACT_533793] ( with total resolution in 55.5% of patie nts) and resolution of hepatic 
inflammation and ballooning degeneration of hepatocytes (100.0 and 88.8% of patients , 
respectively), with histologic improvement including decreases in lobular inflammation and portal/lobular fibrosis ( Barker  2006, Rabl  2012, Hafeez 201 3, Schneck  2016), all in addition 
to functional liver recovery (Alizai 201 5).   
STUDY OBJECTIVES  
The table below list s each objective a long with its  corresponding endpoint.  
 Table 1:  Study Objectives and Endpoints  
Co-Primary Objectives and Endpoints  
Objective  Endpoint  
To evaluate the effect of bariatric surgery on l iver fat 
in adults with non- alcoholic steatohepatitis ( NASH ) 
84 days (12 weeks)  post- surgery  Percent change fro m baseline in liver fat at 84 days  
(12 weeks) post-surgery, as assessed by [CONTACT_533794] 
(MRI -PDFF) 
To evaluate the effect of bariatric surgery on liver 
stiffness in  adults with NASH 84 days (12 weeks) 
post-surgery  Percent change from base line in liver stiffness at 84 days  
(12 weeks) post-surgery, as assessed by [CONTACT_533795] ( MRE ) 
 
Secondary Objectives and Endpoints  
Objectives  Endpoint  
To evaluate the effect of bar iatric surgery on liver fat 
and liver stiffness in adults with NASH 84 days 
(12 weeks)  post-surgery  Percent change from baseline in l iver fat and liver 
stiffness at  84 days (12 weeks) post-surgery, as assessed 
by [CONTACT_21699]®-derived Controlled Attenuation 
Parameter (CAP™) and stiffness  
   
Current Version Dat e: 24OCT2019  IRBNet #:  1000376  
Previous Version Date: 05SEP  2019  Page 10 of 46 
Research Study protocol template version date 11/3/[ADDRESS_693171] -surgery (42 days [6 weeks], 
84 days [12 weeks], 182days [26 weeks], and 364 days 
[52 weeks]), as assessed by:  
• FibroScan®-derived CAP™ and stiffness   
• MRI -PDFF, magnetic resonance spectroscopy 
intrahepatic lipid ( MRS -IHL), and MRE  
To evaluate the effect of pre -surgical dietary 
intervention on liver fat and liver stiffness in adults 
with non-alcoholic fatty liver disease ( NAFLD ) 
(entire study population)  Percent change in liver fat and liver stiffness between 
screening and baseline, as assessed by:  
• FibroScan®-derived CAP™ and stiffness  
• MRI -PDFF  and MRE  
 
Exploratory Objectives and Endpoints  
Objective  Endpoint  
To evaluate the  effect of bariatric surgery 
on extrahepatic adipose depots, s keletal muscle, 
and liver fibro -inflammatory state in adults with 
NASH over time  Percent change from baseline, over time post -surgery 
(42 days [6 weeks], 84 days [12 weeks], 182 days 
[26 weeks], and 364 days [52 weeks]) , in: 
• extrahepatic volumes of adipose tissue and skeletal muscle as assessed by [CONTACT_533796]  
• corrected -T1 of the liver as assessed by 
[CONTACT_533797], over time post -surgery 
(42 days [6 weeks], 84 days [12 weeks], 182 days 
[26 weeks], and  364 days [52 weeks]) , in Disease 
Severity Index ( DSI) and % -shunt as assessed 
by [CONTACT_533798] e ffect of bariatric surgery on gut 
microbiome in adults with NASH over time  Change from baseline, over time post -surgery (42 days 
[6 weeks], 84 days [12 weeks], 182 days [26 weeks], 
and 364 days [52 weeks]) , in stool sample:  
• composition (shotgun analysis of microbiome DNA)  
• functionality (shotgun analysis of microbiome RNA)  
• metabolites of microbiota  
To evaluate the  effect of bariatric surgery 
on circulating metabolomics, protein biomarkers, 
and liver enzymes in  adults with NASH over time  Percent change from baseline, over time post -surgery 
(42 days [6 weeks], 84 days [12 weeks], 182 days 
[26 weeks], and  364 days [52 weeks]) , in: 
• OWLiver, and OWLiver Care metabolomics panels 
from OWL  
• pro-collagen protein fragments pa nel from Nordic 
Bioscience  
• aspartate aminotransferase ( AST ) and alanine 
aminotransferase ( ALT ) enzymes  
To evaluate pre -surgery differences in biomarker 
signatures between adults with NASH and those 
with non-NASH NAFLD   Difference measures between subject groups at basel ine 
for: 
• FibroScan®-derived CAP™ and stiffness  
• magnetic resonance ( MR)-derived measures  
• circulating biomarker measures  
• gut microbiome measures  
To assess predictive natur e of measured biomarkers 
to non -invasively characterize disease state in adults 
with NAFLD (entire study population)  Correlative relationship between disease pathobiology 
as assessed from histopathology measures of biopsy 
samples (liver) collected during bariatric surgery and any 
other secondary or exploratory endpoints  
   
Current Version Dat e: 24OCT2019  IRBNet #:  1000376  
Previous Version Date: 05SEP  2019  Page 11 of 46 
Research Study protocol template version date 11/3/[ADDRESS_693172] of bariatric surgery  on liver fat  
in adults with non -alcoholic fatty liver disease 
(NAFLD) (entire study population)   Percent change in intrahepatic lipi[INVESTIGATOR_533773] (MRS -IHL) 
To evaluate the ability of a diffusi on-based MRI 
method to non -invasi vely measure liver stiffness 
in adults with NAFLD (entire study popula tion)  Correlation between liver stiffness measures derived 
from diffusion -based MRI and those methods that impart 
a mechanical perturbation to tissue, namely:  
• FibroScan®-derived stiffness  
• MRE  
 
STUDY DESIGN  
Research Design  
This is a n on-randomized, single- site, biomarker methodology study in subjects with  
presumed NAFLD and NASH undergoing bariatric surgery.  Participants will 
undergo bariatric s urgery along with all pre - and post -surgery medical visits and  standard 
of care laboratory assessments.   
Over the course of this study, longitudinal assessments of subjects wit h NASH 
or non-NASH NAFLD will be performed using a battery of non- invasive circulating, 
functional, imaging, and microbiome- based assays to evaluate physiologic changes that 
occur in response to bariatric surgery.   The specific imaging to be employed in this study incl udes FibroScan
® and MRI  to 
noninvasively evaluate the effects of bariatric surgery on the liver and on extra-hepatic 
depots of adipose tissue.  The FibroScan® instrument applies a technique referred to as 
vibration -controlled transient elastography (VCTE™) to simultaneously derive measures 
of stiffness for the assessment of liver fibrosis, and of ultrasound wave attenuation for the assessment of liver steatosis (a measure referred to as the co ntrolled attenuation 
parameter [ CAP™ ]).  Magnetic resonance ( MR) assessments will apply scanning 
methods to interrogate steatosis, inflammation, and fibrosis of the liver through measures derived from proton density fat fraction (MRI -PDFF), proton spectroscopy (MRS- IHL), 
T1 relaxometry using the LiverMultiScan (LMS) pro tocol, and MR elastography (MRE), 
respectively.  To assess effects of surgical intervention outside the liver, MRI evaluation of extra- hepatic adipose tissue volumes within visceral and subcutaneous regions, 
and skeletal muscle will be quantified.  
This stu dy will also collect blood samples to investigate the  effect of bariatric surgery 
on longitudinal profiles of several categories of circulating biomarkers and evaluate their utility in tracking NASH disease regression.    
Recent advances in metabolomic tes ting methodologies and associated analysis 
algorithms have led OWL Metabolomics to define lipi[INVESTIGATOR_533774], and for differentiating NASH from simple steatosis (Barr 2012).  
Analysis of serum  lipid metabolites by [CONTACT_533799] a recent study of biopsy-proven NAFLD patients.  Findings from that  study 
demonstrated that the OWLiver Care analysis is able to discriminate between NAFLD 
   
Current Version Dat e: 24OCT2019  IRBNet #:  1000376  
Previous Version Date: 05SEP  2019  Page 12 of 46 
Research Study protocol template version date 11/3/2016  
 and healthy liver , while the OWLiver analysis is able to discriminate between NASH 
and simple steatosis, both with AUROC > 0.9 (Crespo 2016).  Similarly, assay 
development to quantify circulating proteins associated with tissue remod eling has led 
Nordic Bioscience to identify a panel to interrogate fibrogenic activity (Nielsen 2013).  
In a recent clinical study of patients with advanced hepatitis C, profiling markers related 
to both synthesis and degradat ion of the extracellular matrix (in the form o f collagen 
pro-peptides and collagen degradation fragments) was found to serve a prognostic role by 
[CONTACT_533800]-fibrotic therapy (Nielsen  2015).  As similar fibrogenic  processes are likely active in NAFLD patients that 
are at risk of advancing to NASH, there is interest to determine if the panel may provide similar prognostic value, and if assessed longitudinally, ins ight to therapeutic efficacy 
in advance of histologic al or clinical assessments.    
This study will also monitor the effect of bariatric surgery on liver function as characterized by [CONTACT_533801] L iver Diagnostic Kit test.  
This diagnostic test is being developed as a quantitative assay of liver function that 
involves the co- administration of stable isotopes of cholate:  13C -cholate 
[cholic acid -24-13C, IND #65,121] (administered intravenously [ IV]); and 4d- cholate 
[cholic acid -2,2,4,4-d4, IND #65,123] (administered orally).  Following the dual- cholate 
administration, timed blood samples are collected over a 90-minute period.  Liquid chromatography- mass spectrometry (LC -MS) analysis of the samples will generate 
kinetic measures of cholate clearance.  Clearances of IV - and orally- administered cholate 
are liver -specific functions dependent upon systemic and portal blood flows, respectively, 
and hepatocyte uptake.  The primary output of the test is a summary parameter referred to as the Disease Severity Index (DSI), which is calculated from the clearance rates.  DSI values increase with impairment of cholate clearances and have been shown to correlate 
with increasing severity of liver disease and risk for adverse clinical outcomes 
(Helmke  2015).   A standard hepat ic panel used clinically to monitor liver health will also 
be collected.  
The effect of bariatric surgery on gut microbiome will be assessed through stool sample 
assays for composition, functionality, and metabolites of microbiota (both stool and circulatin g).  Alterations to the intestinal microbiota have been found to contribute to the 
pathogenesis of many liver diseases, including NAFLD ( Schnabl 2014).  Though the 
mechanism through which microbiota may negatively or pos itively influence the onset of 
NAFLD is not fully understood, it is plausible that investigation of the bac terial dysbiosis 
that arises in  response to bariatric surgery may provide insight to: (1) novel approaches to 
inhibit pathways that promote disease progression in NAFL D, or (2) identification of 
non-invasive biomarkers to identify patients at risk for progression to NASH.   
The only non- standard of care procedures that will occur d uring bariatric surgery is a  
liver biopsy for histology and exploratory analyses.  In the post -surgery period, the only 
non-standard of care activities will be those related to the imaging and sample collection 
for monitoring of liver health with the specified biomarkers.   Research -related procedures 
occurring before and after surgery are detailed below. 
   
Current Version Dat e: 24OCT2019  IRBNet #:  1000376  
Previous Version Date: 05SEP  2019  Page 13 of 46 
Research Study protocol template version date 11/3/2016  
  
Study Agent, Device, and/or Intervention Description  
To achieve one of our exploratory objectives, we will use the HepQuant SHUNT Liver 
Diagnostic Kit to quantitatively assess changes in liver function over time. The HepQuant SHUNT Liver Diagnostic Kit is an investigational device kit with an Investigational New Drug (IND) and Investigational Device Exemption (IDE) held by [CONTACT_533802], LLC. The US FDA originally in [ADDRESS_693173] as a drug. As such there are INDs for the drug components of the kit currently held by [CONTACT_533802], LLC: Cholic Acid-
24-13C (IND # 65,121) and Cholic Acid-2,2,4,4-d4 (IND # 65,123). In 2015, the FDA 
re-classified the HepQ uant SHUNT Liver Diagnostic kit as a diagnostic device and drug 
combination product. Therefore, the FDA requires that new clinical trials apply for an 
IDE, not an IND.  Please refer to Investigator Brochure and email from manufacturer submitted with this package.  
 
As sponsor of the IND and IDE, HepQuant, LLC. is respons ible for FDA filings. 
Investigator compliance with Federal Food, Drug, and Cosmetic Act and the implementation regulations (Title 21 of the Code of Federal regulations, 21 CFR Part 50, 21 CFR Part 812, and 21 CFR Part 54) is defined in an Investigator Agre ement with 
HepQuant, LLC. All investigational products will be stored in the secured pharmacy at the Translational Research Institute for Metabolism and Diabetes ( TRI-MD). All 
products and procedures will be either handled and/or administered by [CONTACT_533803] a study doctor.  
  All other interventions are either standard of care for bariatric surgery or listed below for 
research purposes.  
 
Study Site(s)/Location(s) and Number of Subjects  
AdventHealth Orlando  site location s (campus, physician offices, etc.):  
• Celebration Health  
• Translational Research Institute for Metabolism and Diabetes  
Estimated number of participants:  35  
The study will enroll 25 participants with NASH for the full stu dy and 10 participants 
with non- NASH [NAFLD or normal] to serve as controls.  The [ADDRESS_693174]- surgery  study visits  and may 
become part of the 10 participants non- NASH group  (see Figure 1 below) . Additional 
participants may be recruited if the analysis of the primary end point (12 weeks) reveals larger variability than anticipated.   
   
Current Version Dat e: 24OCT2019  IRBNet #:  1000376  
Previous Version Date: 05SEP  2019  Page 14 of 46 
Research Study protocol template version date 11/3/2016  
 Multi -Site Research  Logistics/Communication Plan 
 Not applicable. 
Research Conducted in a Foreign Country 
Not applicable. 
Community- Based Participatory Research  
 Not applicable. 
SUBJECT SELECTI ON 
Vulnerable Populations  
Not applicable. 
Inclusion Criteria  
To be eligible for this study , participants  must meet the following inclusion criteria:  
1. Age ≥ 18 years 
2. Undergoing bariatric surgery (Roux- en-Y or gastric sleeve only) as part of clinical 
care. 
3. Negative β hCG - level  (female participants who become pregnant during the study 
will be withdrawn)  
4. MRI :  
• for initial assignment to  NASH cohort – 
o MRI -PDFF ≥8% (data generated by [CONTACT_533804]- MD) , and  
o magnetic resonance elastography ( MRE ) ≥3.00 kPa  (Chen  2011, Dulai 
2016, Loomba 2016, Costa -Silva 2018) ; or 
o MRE ≥  2.70 kPa ( Chen 2011) with at least one of the following risk 
factors for NASH:  
 type 2 diabetes 
 metabolic syndrome  
 ALT ≥  1.5 times the upper limit of normal  
 Fibrosis -4 score suggestive of NASH (advanced fibrosis): Age ≤  35: 
score not applicable; Age ≥  36: > 2.67 ( McPherson 2017)  
 AST to platelet ratio of ≥  0.7, which is suggestive of NASH 
(significant fibrosis) ( Lin 2011) 
 
• for initial assignment to  NAFLD or normal participants cohort – 
o No requirement for minimum MRI- PDFF, and  
o MRE ≤  2.50 kPa ( Chen  2011, Dulai 2016, Loomba 2016, Costa -Silva 
2018) 
Final Cohort assignment to be confirmed based upon results of liver biopsy 
(See Figure 1) 
5. Histopathology assessment of liver biopsy that confirms NASH diagnosis 
   
Current Version Dat e: 24OCT2019  IRBNet #:  1000376  
Previous Version Date: 05SEP  2019  Page 15 of 46 
Research Study protocol template version date 11/3/2016  
 6. Hemoglobin A1c ( HbA1 c) ≤9.5% 
7. Fasting triglycerides  ≤400 mg/dL (4.5 mmol/L)  
8. Body mass index ( BMI ) ≥35kg/m2 (– 0.5 kg/m2) when qualified for bariatric 
surgery 
9. Able to speak and understand written and spoken English 
10. Understands the procedures and agrees to participate by [CONTACT_533805]  
11. Willing and able to c omply with scheduled visits, laboratory tests, and other study 
procedures  
Exclusion Criteria  
Exclude participants from this study if any of the inclusion criteria are not met, or if any of the following are observed: 
1. Participation in other studies involving investigational drug(s) within 30 days  
prior to Screening Vis it 1 
2. History of regular alcohol consumption exceeding 14 drinks/week for females or 21 drinks/week for males within the previous 6  months  
(1 drink = 5 ounces [150 mL] of wine, 12 ounces [360 mL ] of beer , or 1.5 ounces 
[45 mL ] of hard liquor ) 
3. A total score of ≥ [ADDRESS_693175] ( AUDIT ) 
questionnaire ( Appendix B ), indicating harmful or hazardous ethanol 
consumption  
4. A positive urine drug test for illicit drugs  
5. Clinical evidence of hepatic decompensation , including, but not limited 
to esophageal varices, ascites, or hepatic encephalopathy  
6. Evidence of other forms of c hronic liver disease ( including laboratory tests  
as assessed by a sponsor- identified laboratory , and confirmed  with  a single repeat, 
if needed ): 
 Hepatitis  B virus (HBV):  defined by [CONTACT_107077]  B surface antigen 
(HBsAg)  
 Hepatitis  C virus (HCV) : As defined by a clinical history of previous 
diagnosis of Hepatitis C (treated or untreated) or a  positive Hepatitis C 
antibody (HCVAb) .  
 Human Immunodeficiency Virus (HIV ) infection, defined as presence of HIV 
antibody 
 Known diagnosis of primary biliary cirrhosis, primary sclerosing cholangitis, autoimmune hepatitis, or overlap syndrome 
 Alcoholic liver disease  
 Known diagnosis of hemochromatosis 
   
Current Version Dat e: 24OCT2019  IRBNet #:  1000376  
Previous Version Date: 05SEP  2019  Page 16 of 46 
Research Study protocol template version date 11/3/2016  
  Prior known drug-induced liver injury  
 Known or suspected h epatocellular carcinoma  (HCC)  or other liver cancer 
 History of liver transplant, current placement on a liver transplant list, 
or current model of end- stage liver disease (MELD) score >12  
 Histological presence of cirrhosis on a prior biopsy 
7. Diagnosis of type 1 diabetes mellitus  
8. Any malignancy not considered cured, except basal cell carcinoma and squamous cell carcinoma of the skin  (a subject is considered cured if there has been no 
evidence of cancer recurrence in the previous 5 years) 
9. Use of drugs historically associated with non- alcoholic fatty liver disease 
(NAFLD) for ≥1 month  in the previous year prior to Visit 3 (day of Surgery ); 
examples include:  amiodarone, methotrexate, systemic glucocorticoids, 
tetracyclines,  tamoxifen, estrogens at doses greater than those used for hormone 
replacement, anabolic steroids, valproic acid, other known hepatotoxins 
10. Subjects with history of severe claustrophobia impacting ability to perform MRI during the study without mild sedatio n/treatment with an anxiolytic 
11. Subjects who fulfill any of the contraindications for MRI; examples include metal implants, devices, paramagnetic objects contained within the body and excessive or metal -containing tattoos  
12. Unable to participate in MR assessm ents due to physical limitations of 
equipment tolerances (e.g. , MRI bore size and 5 00-pound weight limit) based 
on Investigator’s judgment at screening  
13. Any person unable to lie still within the environment of the MRI scanner or maintain  a breath hold for the required period to acquire images without mild 
sedation/treatment with an anxiolytic  
14. Subjects with any anatomical or pathological abnormality that would either preclude or tend to confound the analysis of study data, including any cl inically 
significant abnormal findings on the MRI obtained at Screening Visit 2 . 
15. Blood donation (excluding plasma donations) of approximately 1 pi[INVESTIGATOR_11731] (500 mL) or more within 56 days prior to Screening Visit 1 (participants may not donate 
blood any time during the study, th rough the final study visit)  
16. Known history or suspected hypersensitivity to human serum albumin, or its preparations.   
17. Investigator site staff members directly involved in the conduct of the study and their family members, site staff memb ers otherwise supervised by [CONTACT_1275], or subjects who are [COMPANY_007] employees, including their family members, directly involved in the conduct of the study 
18. Participants who are NPO status will not receive the HepQuant test  
   
Current Version Dat e: 24OCT2019  IRBNet #:  1000376  
Previous Version Date: 05SEP  2019  Page 17 of 46 
Research Study protocol template version date 11/3/2016  
 19. Presence of any condition that, in the opi[INVESTIGATOR_689], compromises 
participant safety or data integrity or the participant’s ability to complete the 
study. 
 The eligible population for enrollment in the full longitudina l study is subjects with 
biopsy- confirmed NASH.  Liver biopsies will be collected at the time of the bariatric surgery 
procedure; however, in advance of the surgery, screening criteria based on liver imaging assessments will be applied in a sequential manner in effort to help identify eligible s ubjects.   
The MR assessment performed at Screening Visit 2 will serve as the non -invasive qualification 
of subjects with NASH, which will be defined as those having a liver fat -fraction ≥ 8% and liver 
stiffness ≥3.00 kPa or MRE ≥  2.70 kPa ( Chen 2011) with at least one of the following risk 
factors for NASH: type 2 diabetes, metabolic syndrome, Screening labs or labs drawn within 30 days prior to SV2 (ALT ≥ 1.[ADDRESS_693176] to platelet ratio of ≥ 0.7, 
and/or Fibrosis -4 score suggestive of NASH: Age ≤  35: score not applicable; Age ≥  36: > 2.67 
(Lin 2011, McPherson 2017). See Appendix C
 for description of how the scores are calculated.  
The TRI -MD PDFF calculation will be used for determination of eligibility .  Only enrolled 
participants will have their MRI data s ent to AMRA and  Perspectum for PDFF analysis during 
the study timepoints ind icated in Appendix A: Schedule of Events . During the bariatric surgery 
procedure, subject inclusion will be confirmed following histological analysis of the liver biopsy.  Following bariatric surgery, qualifying subjects will undergo periodic assessments out to [ADDRESS_693177] -surgery.  In addition, subjects who either (1) do not meet the screening criteria for 
presumed NASH prior to surgery, or (2) meet the initial screening criteria, but do not meet the biopsy criteria for N ASH diagnosis, will be considered for inclusion in a non- NASH cohort 
whose baseline assessments and perioperative biopsies will serve as control data, but for which no post- surgical longitudinal assessments will be performed.   
A summary of the screening criteria for subject eligibility is provided in the decision tree diagram provided in Figure [ADDRESS_693178] Eligibility  
 

   
Current Version Dat e: 24OCT2019  IRBNet #:  1000376  
Previous Version Date: 05SEP  2019  Page 18 of 46 
Research Study protocol template version date 11/3/2016  
 RESOURCES AVAILABLE 
Site Initiation/Study Specific Training 
All TRI -MD faculty and staff assisting with the research will be trained on the protocol 
design, study  procedures, and their duties and functions pertaining to this study .  
All training will be documented in accordance with AdventHealth Orlando ORA SOP 06 
(Research Personnel Selection, Qualification, Responsibilities, and Training) and 
WI.031.50.[ADDRESS_693179] operating procedures ( SOPs ), work instructions ( WIs), and study- specific procedures ( SSP)- TRI-
MD.  These polices include plans for ongoing discussion of issues throughout the duration of the study such as reportable new information, implementing amendments, study progress, etc. 
STUDY PROCEDURES  
Subject Recruitment and Screening 
Recruitment methods utilized may include, but are not limited to , the following: 
electronic medical records searches; advertising in multiple media (such as print ads, 
flyers, brochures, posters) ; radio ads; television spots; and internet advertising  (including 
social media).  All advertising materials will be submitted to the Institutional Review Board ( IRB) for review prior to using or publishing them.  
Recruitment efforts will follow AdventHealth Orlando  recruitment standard operating 
procedures ( SOPs ) for research.   AdventHealth  Orlando employees will not be 
individually targeted nor excluded from study participation based on employment.  AdventHealth Orlando employees who engage the TRI-MD asking to participate in the study will be processed per standard consent procedures for participants.   In addition, during the consent process, the study staff will review standard 
consent language stating that an empl oyee’s participation or lack of participation in the 
study will not affect their employment status or relationship with AdventHealth Orlando.    
Consent Process  
All study staff delegated the authority to obtain informed consent will follow HRP -802 
(Investigator Guidance: Informed Consent) and HRP-803 ( Investigator Gu idance: 
Documentation of Informed Consent). 
Non-English Speaking Subjects  
Not applicable as the study will only target English- speakers.  
Subjects who are Not Yet Adults ( Infants, Children, Teenagers) 
Not applicable. 
Cognitively Impaired Adults 
Not applicable. 
   
Current Version Dat e: 24OCT2019  IRBNet #:  1000376  
Previous Version Date: 05SEP  2019  Page 19 of 46 
Research Study protocol template version date 11/3/2016  
 Adults Unable to Consent  
Not applicabl e. 
Documentation of Informed Consent Process  
Documentation of the informed consent process is required to establish that the 
participant  was accurately and adequately informed and that no study- related pro cedures 
were initiated prior to obtaining informed consent.   A re search team member will note 
in the source documentation the consent process, the date consent was obtained , and that 
consent was obtained prior to initiating any research procedures. 
Waiver of Written Documentation of Consent or Waiver of Consent  
Not applicable. 
Prohibitions and Restrictions  
During study participation through the final study visit, subjects may not: 
• donate blood 
• use any investigational agent 
• become pregnant (female subjects only) 
Randomization  
Not applicabl e.  
STUDY VISITS  
Procedures and assessments by [CONTACT_533806].  For additional details and specific time points, see the Detailed Analytical/Clinical Procedures  section 
and Appendix A: Schedule of Events , respectively.  
Screening Visit 1 may occur during initial consultation at Celebration Health, or as a 
combination visit (SV 1 and SV 2) at TRI- MD.  The s urgery ( Visit 3) will occur at 
Celebration Health , with  all remaining visits occurring  at TRI -MD. 
Screening Visit  1 (SV1)  
The following procedures may be performed per standard of care during or after  the 
initial consultation visit for determination of eligibility for bariatric surgery . The data will 
be collected as part of this  research study: 
• physical examination 
• height and body weight measured 
• body mass index (BMI) calculated  
• vital signs measured  
• order provided for standard of care laboratory assessments  
o these tests may be repeated 2 –3 weeks before Surgery  
   
Current Version Dat e: 24OCT2019  IRBNet #:  1000376  
Previous Version Date: 05SEP  2019  Page 20 of 46 
Research Study protocol template version date 11/3/2016  
 Signed informed consent will be obtained from interested participants who  will then 
undergo the following procedures during their regularly scheduled initial consultation:  
• assess ment of  participant eligibility  
• demography collection 
• adverse event (AE)/concomitant medication review  
Screening Visit 2 (SV2) 
This visit will  occur as soon as possible after SV1 , or as a combination with SV1 , upon 
final determination of eligibility for bariatric surgery and based on convenience for 
participant.  Any procedures required for eligibility that are not performed during SV1 
will be d one at SV2. The following procedures will be performed after an overnight fast: 
• continued assessment of participant eligibility  
• physical examination 
• single supi[INVESTIGATOR_32832]  
• height and body weight measured 
o Height will be repeated to ensure all future BMI comparisons are based on 
TRI-MD’s calibrated scales and stadiometer.  
• body mass index (BMI) calculated  
• drug, alcohol, tobacco screen/AUDIT questionnaire 
• AE/concomitant medication review  
• blood collection for screening laboratories, including any the laboratory assessments at SV1  were  not completed for any reason 
• urinalysis  
• urine pregnancy test 
• urine drug screen  
• FibroScan
® 
• MRI  
 
Combination of Screening V isit 1 and Screening V isit 2 – if the initial 
surgery consultation at CH has been previously co mpleted , SV1 and SV 2 may be 
combined and completed at TRI- MD. All activities from SV1 and SV2 will be completed 
on the same day without duplicating activities.   
Baseline Visit 1 (BLV1)  
This visit will occur within [ADDRESS_693180]: 
• AE/concomitant medication review  
• body weight measured 
• BMI calculated  
• single supi[INVESTIGATOR_533775]  
• urine pregnancy test 
   
Current Version Dat e: 24OCT2019  IRBNet #:  1000376  
Previous Version Date: 05SEP  2019  Page 21 of 46 
Research Study protocol template version date 11/3/2016  
 • blood collection for hepatic panel 
• blood collection for OWLiver Care, OWLiver, and comprehensive metabolomic 
panel from OWL Metabolomics  
• blood collection for pro- collagen protein fragmen ts panel from Nordic Bioscience  
• HepQuan t SHUNT Dual Cholate Liver Diagnostic test  
• blood collection for biobanking 
• stool collection during visit or with an at- home kit after the visit  
• standard of care pre-surgery diet (will begin after Baseline Visit 1, but before 
Baseline Visit 2)  
Baseline Visit 2 (BLV2)  
This visit will occur within the final [ADDRESS_693181] : 
• AE/concomitant medication review  
• body weight measured 
• BMI calculated  
• single supi[INVESTIGATOR_533776]  
• urine pregnancy test 
• blood collection for hemoglobin level  
• blood collection for hepatic panel  
• blood collection for OWLiver Care, OWLiver, and comprehensive metabolomic 
panel from OWL Metabolomics  
• blood collection for pro- collagen protein fragmen ts panel from Nordic Bioscience  
• If BLV1 is not completed, stool collection will occur during this visit or with an at -
home kit after the visit  
• FibroScan® 
• MRI 
Surgery (V3) – Day [ADDRESS_693182] of care for bariatric surgery: 
• body weight measured 
• BMI calculated  
• single supi[INVESTIGATOR_533776]  
• urine pregnancy test 
• Roux- en-Y or gastric s leeve will be perfor med using standard procedures by [CONTACT_533807] . 
The following additional research procedures will be performed: 
• Two liver biops ies for clinical histology and exploratory endpoints/biobanking 
   
Current Version Dat e: 24OCT2019  IRBNet #:  1000376  
Previous Version Date: 05SEP  2019  Page 22 of 46 
Research Study protocol template version date 11/3/[ADDRESS_693183]-Surgery Visit s (V4) – Day 42 ±7 days (6 weeks)  
 (V5) – Day 84 ±7 days (12 weeks)  
 (V6) – Day 182 ±14 days (26 weeks) 
 (V7) – Day 364 ±14 days (52 weeks) 
The following procedures will be performed after an overnight fast: 
• AE/concomitant medication review  
• body weight measured 
• BMI calculated  
• single supi[INVESTIGATOR_533776]  
• urine pregnancy test 
• blood collection for hepatic panel 
• blood collection for OWLiver Care, OWLiver, and comprehensive metabolomic 
panel from OWL Metabolomics  
• blood collection for pro- collagen protein fragments panel from Nordic Bioscience 
• HepQuant SHUNT Dual Cholate Liver Diag nostic test  
• blood collection for biobanking 
• home stool collection during visit or with an at home kit after the visit  
• FibroScan® 
• MRI 
DETAILED ANALYTICAL/CLINICAL PROCEDURES  
Physical Exam ination and Medical History 
A standard of care physical examination with collection of comprehensive medical 
history will be performed by a study physician, physician assistant, or nurse practitioner. 
Drug, Alcohol, Tobacco Screen and AUDIT Questionnaire 
Participants will be questioned regarding  their consumption of  illicit drugs, alcohol, 
and tobacco use.  Participants will also complete the Alcohol Use Disorders Identification 
Test (AUDIT) questionnaire  to screen for harmful or hazardous ethanol consumption.  
Appendix B  shows the questions the participants will be asked along with the scoring 
methods; the latter will not be provided to participants.  
Height, Body Weight, BMI Calculation  
Body weight (calibrated scale) and height will be obtained while in a gown, with undergarments, without shoes.  BMI will be calculated based on subject’s body weight 
and standing height [BMI  = body weight in kg ÷ height in m
2].  
Vital Sign Measurements 
Single supi[INVESTIGATOR_533777]/heart rate, systolic/diastolic blood pressure, respi[INVESTIGATOR_697], and oral/tympanic temperature.   Pulse and  blood pressure 
(using an appropriate size cuff for the subject’s  arm circumference) will be measured 
with participants  in a supi[INVESTIGATOR_55848] [ADDRESS_693184].   
   
Current Version Dat e: 24OCT2019  IRBNet #:  1000376  
Previous Version Date: 05SEP  2019  Page 23 of 46 
Research Study protocol template version date 11/3/2016  
 Screening Laboratory Assessments 
The following laboratory assessments are utilized to assess eligibility  during the 
screening process:   
• complete blood count ( CBC)  
• platelet count 
• comprehensive met abolic panel (CMP)  
• lipid panel 
• prothrombin (may be prothrombin time [PT]/ international normalized ratio 
[INR]/ partial thromboplastin time [PTT ]) 
• activated part ial thromboplastin time (APTT) 
• HbA1c  
• thyroid stimulating hormone (TSH) with reflex to thyroxine ( T4) 
• parathyroid hormone (PTH)  
• urine pregnancy test 
• urine drug test  
• HIV antibody 
• HBsAg  (Hepatitis B antigen ) screen  
• HCVAb  (Hepatitis C antibody)  
These are used concomitantly to assess general patient health  and determine study 
eligibility (Inclusion/Exclusion Criteria ).   
 
Circulating Biomarkers  
Assessment of circulating biomarkers will be performed  at scheduled visits as outlined 
in  Appendix A: Schedule of Events . 
Metabolomics:  A comprehensive panel of serum metabolites will be measured at OWL 
Metabolomics.  This panel of biomarkers allows for the identification  and monitoring of  
disease progression / regression based on changes in the metabolomic signature [CONTACT_533831].  The panel includes OWLiver
®, OWLiver®Care , 
and approximately 600 additional metabolites  for exploratory purposes.  This testin g 
paradigm will allow for a comprehensive evaluation of changes in liver health and metabolic status after bariatric surgery/  
Hepatic Panel:  This panel includes total protein, albumin, globulin, albumin/globulin ratio, total bilirubin, direct bilirubin, alkaline phosphatase, alanine aminotransferase 
(ALT ), and aspartate aminotransferase ( AST ).  It is a  standard clinical test commonly 
used to determine the health of the liver.  
Pro-Collagen Protein Fragments:  At minimum, we will measure two pro -collagen 
protein  fragments at Nordic Bioscience - Pro C3 and ProC6.  Nordic Bioscience has 
developed a panel of biomarkers of extracellular matrix turnover that could provide 
important information about liver health including inflammation, disease prognosis, 
efficacy of interventions, and fibrogenesis.   
   
Current Version Dat e: 24OCT2019  IRBNet #:  1000376  
Previous Version Date: 05SEP  2019  Page 24 of 46 
Research Study protocol template version date 11/3/2016  
 We will bank additional samples for future assessment of novel biomarkers 
and mechanisms.   
Details regarding type of sample, matrix, tubes, volume and sample management 
conditions for collection w ill be described in the  Laboratory Manual.   
Magnetic Resonance Imaging and Spectroscopy (MRI)  
Assessment by [CONTACT_533808] A: 
Schedule of Events  and will include measures of liver fat fraction, liver stiffness, liver 
relaxometry, and body composition.  The goal of this test is to assess liver lipid  content 
and stiffness, and perform volumetric fat quantitation  using an Achieva 3T 
MRI/Multinuclear MRS (Philips, Andover, MA).  Scans wi ll be performed under 
standardized conditions with participan ts in a supi[INVESTIGATOR_2547], using the quadrature body 
coil and the torsoXL coil .   
Standard MR  images will be completed to obtain anatomical images for spectroscopy 
voxel and image slice localization  and volumetric measurements of fat, muscle, organs, 
and bone in the participant’s abdomen.    Low resolution scans will be taken to determine appropriate posi tioning for high resolution images.  I maging  sequences will then be 
performed over  the participant’s body, approximately spanning from the neck to the 
knees.  The MRE driver will be placed on the participant’s abdomen for the duration of the MR acquisition , and engaged during the MRE acquisition, for up to 3 tot al minutes.    
Images which are degraded due to motion may be repeated as time permits.  The individual MRI scans and acquisition parameters are detailed in the Imaging Study -
Specific- Procedure ( SSP) and Scan Parameters documents.  To minimize the potential 
for confounding factors to affect the measurements, MR scans will be conducted following a  fast (except water) of at least 4 hours and as much as practically possible, at 
the same time of day relative to the screening assessment (±2 hours).  Attempts will be 
made to ensure longitudinal assessment of an individual subject are performed by [CONTACT_308533].  
Total MR I scan time will be approximately 90 minutes. 
 For eligible participants at SV2, and BL V2, V4, V5, V6 and V7 as indicated in Appendix 
A: Schedule of Events , images will be sent for external analysis . Images will be sent to 
Advanced MR analytics AB (AMRA) for adipose tissue distribution analysis and steatosis quantification from the PDFF scans and to Perspectum Diagnostics for quantitative, multiparametric MRI analysis using LiverMult iScan, to determine their 
proprietary corrected T1 values, iron content, and liver steatosis. 
 
 
FibroScan® 
Approximation of liver fat and stiffness by [CONTACT_533809] n® will occur at scheduled visits 
outlined in Appendix A: Schedule of Events .  Fibroscan® uses ultrasound based VCTE™ 
(vibration -controlled transient elastography) to obtain  Liver Stiffness Measurement 
(LSM) and Controlled Attenuation Parameter (CAP ™); LSM is correlated to liver 
   
Current Version Dat e: 24OCT2019  IRBNet #:  1000376  
Previous Version Date: 05SEP  2019  Page 25 of 46 
Research Study protocol template version date 11/3/[ADDRESS_693185] (50 MHz).  The  wave produces a mechani cal 
deformation that moves towards and then through the liver.  The  velocity of the shear 
wave in the liver is measured and is directly proportional to its stiffness (stiffer tissue, faster velocity).  Using a proprietary algorithm, the device determines w hether the shear 
wave propagated into the liver and is valid.  The LSM, expressed in kilopascals (kPa), is only calculated on valid measures.   Liver stiffness me asurement values range from 
1.5 to 75 kPa; lower values indicate a more elastic liver.  CAP ™ measures the ultrasonic 
attenuation coefficient in the forward and return path through the liver at 3.5 MHz and is  expressed in decibels/meter.  CAP ™ is evaluated simultaneously with LSM using 
the same radio -frequency data and is only appraised if the LSM is “valid.”   The  specific 
FibroScan
® model being utilized  is the 502 Touch (Echosens, Paris, [LOCATION_009]).   
Participants  will lie on their back (supi[INVESTIGATOR_050]) with their right arm raised  in abduction 
to increase the intercostal space.  A water -based gel will be app lied to  the skin and the 
transducer probe will then be placed on the participant’s skin, in the intercostal space 
directly above the liver with slight pressure.  At  least t en valid  measurements will be 
taken and the results will be immediate.  To minimize the potential for confounding 
factors to affect the measurements, Fibro Scan® will be conducted following a fast 
(except water) of at least 4 hours and as much as practically possible, at the same time of day relative to the screening assessment (±2 hours).  Only study staff members who are trained in the use of FibroScan
® are permitted to acquire measures of liver stiffness and 
CAP™.  Additionally, a ttempts will be made to ensure longitudinal assessments of 
an individual subjec t are performed by [CONTACT_332019] .   
The test takes a total of about 10 minutes , with total scan time (including setup) of 
approximately 30 minutes.   
Details associated with the FibroScan® scanning protocol are documented in the Imaging  
SSP.   
Quantitative Liver Function Test (HepQuant SHUNT Dual Cholate 
Liver Diagnostic Kit ) 
The HepQuant SHUNT Dual Cholate Liver Diagnostic Kit  will be administered  at 
scheduled visits outlined in Appendix A: Schedule of Events .   
An indwelling peripheral venous catheter is used to collect a baseline Pre-Dose blood 
sample.  Then, 20 milligrams of 13C-cholate is administered intravenously through the catheter, and 40 mi lligrams of d4 -cholate is simultaneously administered orally, 
as detailed in the HepQuant Instructions for Use (IFU).  F ive timed blood samples drawn 
at 5, 20, 45, 60, and 90 minutes after the simultaneous dosing are utilized to measure the cholate pharmacokinetic (PK) clearances.   
Total time for test setup and execution is expected to be 2 hours.  
Additional details on sample processing are documented in the Laboratory Manual. 
   
Current Version Dat e: 24OCT2019  IRBNet #:  1000376  
Previous Version Date: 05SEP  2019  Page 26 of 46 
Research Study protocol template version date 11/3/[ADDRESS_693186] for 
research purposes.  The second liver biopsy will be utilized for gene expression 
analysis via RNA sequencing (RNA-Seq).  Any remaining tissue will be archived for 
future analyses.   
 
A “Time Out” will be called during surgery where the surgeon and a research staff member will verify that the patient undergoing surgery is a research participant that is actively enrolled. The liver biopsy will not be collected for research purposes unless the time out is called.  
Collection of the liver biopsies will add approximately 10 minutes to the usual 
bariatric surgery  procedure.   
  
 
Stool Collection 
A stool sample will be co llected at the following time points: Baseline visit 1, Day 42 ±7, 
Day 84 ±7, Day 182 ±14, and Day 364 ±[ADDRESS_693187] the stool sample, a box with cold packs for transport and instructions for collection.  Details of the stool collection kit and methods will be part of the an 
SSP and/or Laboratory Manual.   Once produced, participants will call the study 
coordinator to make arrangements for t he sample to be dropped off.  If  the 
participant is unable to drop off the stool sample, a courier will be set up to pi[INVESTIGATOR_533778].  
STUDY DURATION 
The overall study duration is anticipated to be up to [ADDRESS_693188] baseline visit and  the second baseline 
visit,  and the longitudinal study period will then continue for 12 months . 
The study is projected to begin between May and July 2018, with study completion 
expected 1  year after recruitment of the final participant.  Recruitment of all participants 
is anticipated to take approximately nine months . 
   
Current Version Dat e: 24OCT2019  IRBNet #:  1000376  
Previous Version Date: 05SEP  2019  Page 27 of 46 
Research Study protocol template version date 11/3/2016  
 MATERIALS OF HUMAN ORIGIN:  COLLECTION, 
PREPARATION, HANDLING AND SHIPPI[INVESTIGATOR_533779].  For all study procedures, SSPs will be prepared  or established SOPs or Work Instructions 
will be used .  Samples will be collected and analyzed per the documented techniques 
established at the TRI -MD laboratory, Celebration Health  and the AdventHealth Orlando 
Center for Diagnostic Pathology. 
Biospecimen samples will be stored in ultralow temperature freezers and liquid nitrogen 
dewars or other storage units located at the TRI -MD Laboratory Room 2404.  The 
TRI-MD facility is secured via key card and equipped with a back -up generator system.  
Laboratory personnel in the facility have 24/7 key- controlled access to the laboratory.  
Chain of custody of biospecimen samples is maintained through requisition forms 
and in  the StarLIMS database.  Specimen tubes are coded, and specimen requests and 
distribution are documented.  Access to samples is limited to designated study team members as indicated on the delegation of authority log.  Biological materials will be maintained in a locked and secured area within the TRI -MD facility.  Physical access 
is limited by [CONTACT_533810].  
The biopsy that will be used for histology will be stored at the AdventHealth Orlando Center for Diagnostic Pathology for 10 years per  the College of American Pathologists 
(CAP) protocol.  Histology samples may be sent to a second pathologist for a blinded read for  research purposes.   
A subset of de- identified samples will be provided to our collaborators at  [COMPANY_007] for future 
use as defined below.  
Biospecimens collected for study -related endpoints, will be analyzed/tested at both 
AdventHealth Orlando and outside laboratories/institutions.  Laboratories that will 
analyze de- identified samples may include , but is not limited to :  HepQuant, OWL 
Metabolomics, Jackson Laboratories , and Nordic Bioscience .   
Additionally, remaining biospecimens will be archive d for any additional 
hypothesis-related experimentation or testing for this study, which could not be predicted at the time the protocol was developed.  
Furthermore, if there are any left-over biospecimens after completing the above, they may be archived for the following:  other research (not for this study), but of any type  
(without limitation to disease, process, or research methods).  This other research can take place at AdventHealth Orlando or other institutions.   
Lastly, a predetermined amount of biospecimen samples wil l be collected specifically 
for archiving for future use, such as other research ( not for this study), of any type 
(without limitation to disease, process, or research methods).  This other research can 
take place at AdventHealth Orlando or other institutions.   
The biospecimens collected for this study will be separate d into biospecimen samples 
that will be used for t he study and biospecimen samples that were collected to be 
archived for future use.  After study aims have been achieved and study related endpoints have been measured and analyzed, any remaining biospec imens will be stored at the 
   
Current Version Dat e: 24OCT2019  IRBNet #:  1000376  
Previous Version Date: 05SEP  2019  Page 28 of 46 
Research Study protocol template version date 11/3/2016  
 TRI-MD Laboratory Room 2404 and will also be considered as “archived biospecimens.”  
Archived biospecimens will be used for any additional hypothesis- related 
experimentation or testing for the purposes of this study, consistent with the original 
aims, which cannot be predicted at the time the protocol is developed due to the evolving 
nature of scientific exploration.    
Additionally, archived biospecimen samples may be stored indefinitely for future research.  Archived biospecimens could be used for separate research by [CONTACT_533811].  This 
would be allowed for research of any type (without limitation to disease, process, or research methods) if it has scientific merit as  determined by [CONTACT_533812] -MD Scientific 
Review Committee.    For research outside of AdventHealth Orlando, transfer and chain of custody of the biospecimens are detailed in the Contract with the Funder and in 
associated Vendor Agreements.  In instances where these documents are not available, a 
Material Transfer Agreement (MTA) will be obtained, which will govern the transfer and chain of custody of the biospecimens outside of AdventHealth Orlando. 
STUDY OUTCOME MEASURES (ENDPOINTS)  
Please refer to Table 1 .  
DATA MANAGEMENT AND QUALITY PLAN 
Data De -identification  
Participants will be enrolled using Cerner’s Patient Protocol Manager; the application assigns each participant a unique participant identifier, or “PID ”.  This PID is a  code 
consisting of a combination of numerals and letters, which serves as the identifier for this participant for this research study and links them back to their hospi[INVESTIGATOR_533780] (PHI).  Access to the “ link” between the PI[INVESTIGATOR_29721], 
the PHI, and to the clinical data are only granted to the clinical research team as assigned 
on the Delegation of Authority Log.  All the clinic al research data is recorded 
in a de-identified fashion onto our paper source documents, which is then transcribed 
into our electronic case report forms  (eCRF s).  The e CRF is used for storage (a database) 
and facilitates analysis.  Clinical data generated by [CONTACT_533813], 
and once the data has been transformed into interpretabl e results, it is stored into the 
Clinical R esearch D atabase.Both storage locations are secured and  only accessible to the 
assigned clinical research team.  The “ link” will only be used to re- identify participants in 
the event of a serious adverse event (SA E) requiring identification of a PID and PHI to 
treat the participant.  The “link” will be stored in the Patient Protocol Manager and in Clinical Research Database, where only the TRI- MD research team has access.  These 
secure databases are stored/accessed on the AdventHealth Orlando  password -protected 
computer network.  No one outside of AdventHealth Orlando investigators or researchers will have access to the databases.   
Data Confidentiality, Storage, and Retenti on 
The identity and personal health information will be kept confidential to the extent permitted by [CONTACT_29695]/or regulations and will not be made publicly 
   
Current Version Dat e: 24OCT2019  IRBNet #:  1000376  
Previous Version Date: 05SEP  2019  Page 29 of 46 
Research Study protocol template version date 11/3/[ADDRESS_693189] access to it via limited badge access to the medical records room (paper) or role relationship 
(electronic).  The electronic data is maintained under Adventist Information Technology security controls.   
The duration of study data retention will b e determined by [CONTACT_533814]/or sponsor contract mandate (if applicable).  TRI -MD retention policy is maintained 
in the Records Management Policy.  Electronic de- identified data will be kept 
indefinitely in our data warehouse.   
Data Quali ty 
Data quality and integrity will be governed by [CONTACT_533815] 9001 driven data 
management SOPs.  These SOPs delineate how quality is built into the identification, collection, handling, and processing of the data. 
The types of data collected may incl ude data that are: (a) manually abstracted 
or electronically extracted from medical records, (b) observed in clinical exams, 
(c) obtained from laboratory and diagnostic tests, or from various biological monitoring 
or imaging devices, and (d) patient- reported items.   Each data type can be understood by 
[CONTACT_533816].  Only the SOPs/SSPs and associated workflows applicable to the study will be used.   
Within the study , quality control steps may include:  
• Source Data Verification (SDV) 
• Query Management 
• Parallel Processing by a second party  
• Complete re -processing of a percentage of the data and comparing to the original  
• Change Control (i f changes are made there will be documentation that covers change 
content, rationale, author, time and date) 
Data Sharing (O utside of AdventHealth Orlando)   
This is a AdventHealth -Orlando sponsored clinical study with [COMPANY_007]  as the funder.  De-
identified results from this study will be shared with collaborators at [COMPANY_007] to conclude 
analysis and prepare data for publication.  However, only AdventHealth  Orlando will 
have access to the c linical data and the code to identify the samples and make the link 
betw een lab and clinical data.  The source documentation will remain at TRI -MD.   
Some of the endpoint testing and post- acquisition data analysis will be conducted 
at outside laboratories/institutions  including, but not limited to, OWL Metabolomics, 
HepQuant, Nordic Bioscience, Jackson Laboratories, Perspectum Diagnostics 
   
Current Version Dat e: 24OCT2019  IRBNet #:  1000376  
Previous Version Date: 05SEP  2019  Page 30 of 46 
Research Study protocol template version date 11/3/2016  
 and AMRA.  To  perform these analyses/testing/etc. and to interpret results, certain data 
elements may need to be shared along with the biospecimen samples.  The governance of 
data sharing is detailed in the Contract with the Funder and in associated Vendor 
Agreements.  When these documents are not available, Data Use Agreements (DUAs) or Lab Services Agreements, as appropriate, will be obtained, which will identify the specific data elements to be shared (if any) and will govern the sharing of data related 
to this study.  Data will be de -identified, but a link/code is managed within an electronic 
research management system and maintained by a study coordinator.   
Should archived biospecimens be needed for research outside of AdventHealth Orlando  
that is beyond the details in the Contract with the Funder and in associated Vendor 
Agreements and certain data elements that are connected to the archived biospecimen samples are needed to conduct the research, then DUAs  will be obtained.  The DUAs will 
identify the purpose for data sharing, the specific data elements to be shared, and will govern the sharing of data related to this study.  Data will be de- identified, however a 
link/code is managed within an electronic research management system and maintained by a study coordinator.   
SAMPLE SIZE DETERMINATION 
Sample size calculations are based on the two primary endpoints, percent change in PDFF and MRE.  Based on a literature review it is assumed that the mean percent change from baseline in PDFF at 12 –[ADDRESS_693190] deviation of 30%, the mean change from baseline 
in MRE has a standard deviation of [ADDRESS_693191] a 30% change f rom baseline in PDFF 
and a 0.[ADDRESS_693192] with an alpha level of 0.1, 
there is greater than 99 % power for the PDFF change and greater than 80% power for MRE.  
Investigators are also interested in detecting a positive correla tion between the [ADDRESS_693193] for a correlation greater than zero, with 25 subjects, has greater than 80% power to dete ct 
a correlation of 0.42 or greater.   
STATISTICAL ANALYSIS PLAN 
The following subsection outlines the statistical methods that will be used in the analysis of 
the study data.  Detailed descriptions will be included in the statistical analysis plan (SAP).  
Any deviations from the SAP will be described in the Clinical Study Report (CSR) . 
Summary Analyses 
The number of subjects enrolled, complet ed, and discontinued  from the study will be 
summarized.  For subjects who did not complete the study, the reasons for withdrawal from the study will be presented.  
Demographic and baseline characteristics will be summarized for all enrolled  subjects.  
Continuous variables will be summarized using mean , median, minimum, maximum, 
quartiles , and standard deviation.  Categorical variables will be summarized using 
relative frequency.  Key demographic and baseline variables will be  summarized 
and include, but are not limited to :  age, gender, race, ethnicity, height, weight, BMI,  etc. 
   
Current Version Dat e: 24OCT2019  IRBNet #:  1000376  
Previous Version Date: 05SEP  2019  Page 31 of 46 
Research Study protocol template version date 11/3/[ADDRESS_693194] deviation.  Categorical variables will be summarized using relative frequency.  Mixed model repeated measures analyses using all measured data will be used to explore changes over time, systematic differences, correlations with other endpoints, and time trends.  The models will include baseline values of the measurements 
and other baseline demographic information as deemed necessary.  Intra -class 
correlations between endpoints may also be calculated.  Details of the model and correlation structure will be detailed in the SAP.    
Other exploratory and ad hoc analysis (if done) will be detailed in the CSR  and/or SAP. 
Multiplic ity 
Since this is an exploratory study intended to characterize PDFF and MRE measurements in a bariatric surgery population, no formal hypothesis testing is planned, therefore no multiplicity adjustments will be performed.  P -values will be treated as descriptive 
statistics.  
Missing Data  
Descriptive summary statistics will use all available data.  Repeated measures analyses will also use all available data and are expected to provide unbiased estimates under the assumption that data are missing at random (MAR) under the assumed model.  Examination of informative missing data and sensitivity analyses may be performed if necessary and reported in the CSR.  Multiple imputation (MI) may be used for sensitivity or secondary analyses.  
Analysis Populations 
All enrolled patients will be included in the full analysis set (FAS).  The FAS will be used for all summaries and analys es unless otherwise specified in the SAP or CSR.    
   
Current Version Dat e: 24OCT2019  IRBNet #:  1000376  
Previous Version Date: 05SEP  2019  Page 32 of 46 
Research Study protocol template version date 11/3/[ADDRESS_693195] benefit from taking part in this research study.  
However, the knowledge gained regarding liver disease in bariatr ic surgery patients may 
benefit public health as a whole.  In addition, patients will receive information about their liver health before and after surgery, which may provide some benefit.   
POTENTIAL RISKS  
Intravenous Lines/B lood Draws (e.g., Laboratory  Samples)  
The placement of IV  needles may cause transient pain, vasovagal syncope, and may also 
result in bruising, bleeding, and/or clotting at the site of needle insertion.  The application of direct pressure at the catheterization site will be us ed to help prevent these symptoms.  
There is a possibility that a catheter placement would be unsuccessful or need to be removed.  If this should occur, another catheter would be placed.  It is possible that this may occur more than once during participation in the protocol.  Staff  who are trained  
and certified in the SOP will be used.   
The total blood collected from each participant will be approximately [ADDRESS_693196] Risk 
• All venipuncture will be conducted by [CONTACT_533817].   
Magnetic Resonance Imaging (MRI) and Spectroscopy  
There are no known biological risks associated with MRI  and spectroscopy.  Some 
short -term discomfort may be experienced.  The short- term risks associated with MRI 
are minimal, but include heating, loud noises, and  claustrophobia. Some of the i mages 
requi re the use a soft rubber-like clip attached to your finger to monitor the heart beat in 
order to compensate for cardiac motion.  There are some people who should not undergo 
MRI; the  contraindication is largely based on the presence of  metal objects within  a 
person (i.e., pacemaker, aneurysm clip, metal fragments, etc.).   
Protection Against Risk  
• There will be strict safety screening per TRI -MD SOP 030.500.001 to ensure any 
people with contraindications are excluded from volunteering. 
• Optional MRI Acclimatization :   
If a participant voices any concerns with tolerability of MR I scans, an acclimatization 
session may be performed during a screening visit.  Participants will undergo an  MRI 
acclimation session where they will be asked to lie in the MR I machine, in  a manner 
similar to that required for MR I procedures in this study, to ensure participant  
   
Current Version Dat e: 24OCT2019  IRBNet #:  1000376  
Previous Version Date: 05SEP  2019  Page 33 of 46 
Research Study protocol template version date 11/3/[ADDRESS_693197] be reviewed by [CONTACT_533818].  If the abnormality is confirmed  by [CONTACT_268899], then the participant will be 
instructed to seek medical attention from their health care provider.  The results of the radiology interpretation  will become part of the participant’s medical record.   
FibroScan®  
There are no known risks associated  with FibroScan®.   
Protection Against Risk  
Although there are no known risks, the FibroScan® test will be conducted only by 
[CONTACT_533819].   
Quantitative Liver Function Test (HepQuant SHUNT Liver Diagnostic 
Kit) 
The following includes the known adverse events associated with the use of the 
HepQuant SHUNT Kit:  
1. Risks from the Test Compounds a. Allergic reaction to cholate compounds (theoretical – none yet reported) 
b. Allergic reaction to human serum albumin (HSA)  
c. Reactions could include:  
i. rash  
ii. having a hard time breathing 
iii. wheezing when you breathe 
iv. sudden drop in blood pressure 
v. swelling around the mouth, throat, or eyes 
vi. fast pulse  
vii. sweating  
viii. severe reactions are very rare but a severe reaction (called anaphylaxis) can lead to profoundly low blood pressure and even death 
2. Risks from the Indwellin g Catheter  
a. Pain with placement of catheter  
b. Thrombosed vein 
c. Hematoma  
   
Current Version Dat e: 24OCT2019  IRBNet #:  1000376  
Previous Version Date: 05SEP  2019  Page 34 of 46 
Research Study protocol template version date 11/3/[ADDRESS_693198] Compounds  
Cholates, labeled with stable (nonradioactive) isotopes, occur naturally and are not 
known to have any deleterious or adverse effects when given intravenously or orally in the doses used in HepQuant tests.  The serum cholate concentrations that are achieved by [CONTACT_533820] a fatty meal.  Because cholates are naturally occurring with a  pool size in humans of [ADDRESS_693199] compounds may include: allergic reaction.   
The two cholates used in the HepQuant test for this study are labeled with stable (non-radioactive) forms of carbon and hydrogen that are found in nature and can be measured in blood.  These forms of cholate have been used with FDA Investigational 
New Drug (IND) research studies since 2002, and their use in humans has been monitored since that time.  To date, the cholates used in this study have not been associated with any allergic reactions or side effects.  However, they are still considered experimental and there may be unknown risks. 
Human serum albumin is mixed with the 
13C-cholate for IV  injection.  Some 
individuals may have a known reaction to serum albumin, and will be excluded from 
this study.  Possible AEs  from the HSA may include: allergic reaction s.   
Rare Hypersensitivity Reactions have been reported to human serum albumin preparations and include anaphylaxis, severe anaphylaxis or anaphylactoid reactions, fever, chills, rash, urticaria, pru ritus, angioneurotic edema, and erythema or flushing.  
Individuals who are hypersensitive to albumin preparations, any ingredient in the formulation, or components of the containers should be excluded from this substudy. 
Risk of Transmissible Diseases in P lasma -derived Preparations.  Because human albumin 
is prepared from pooled human plasma, there is a potential to pass human viruses 
(e.g., hepatitis viruses, HIV) to the recipi[INVESTIGATOR_533781] a risk of transmitting Creutzfeldt -Jakob disease (CJD) or its variant CJD (vCJD).  Through donor plasma 
screening and specific procedures like pasteurization to eliminate or inactivate any possible causes have reduced, but not entirely eliminated, the risk of transmission of disease causing agents.  Risk of transmiss ion of viral disease with plasma -derived human 
albumin is considered extremely remote.  No causes of transmission of HBV, HCV, or HIV have been documented following use of commercially available human albumin.  There are no documented cases of CJD or vCJD transmitted through plasma -derived 
preparations (including plasma- derived human albumin); theoretical risk for transmission 
of CJD with commercially available human albumin is considered extremely remote.    
However, no purification method has been shown to be totally effective in removing the risk of viral infectivity from plasma -derived preparations and because new blood-borne 
viruses or other disease agents may emerge which may not be removed or inactivated by [CONTACT_533821], the risks of  human albumin are not entirely known. 
Risks from Indwelling Intravenous Catheter  
   
Current Version Dat e: 24OCT2019  IRBNet #:  1000376  
Previous Version Date: 05SEP  2019  Page 35 of 46 
Research Study protocol template version date 11/3/2016  
 Placing the indwelling intravenous catheter will cause minor pain and discomfort.  
With  any blood draw, there is a small risk of hematoma and a very small risk of a blood 
clot (1  in 100) or infection (1 in 1000).  HepQuant has performed the HepQuant SHUNT 
test or the prototypi[INVESTIGATOR_533782] [ADDRESS_693200] multiple times.  There has never been an adverse event  (AE)  - the r isk from the 
test is very small.  Possible adverse event from the placement of an indwelling catheter may include:   hematoma at injection site.   
Special Considerations in Bariatric Populations  
After bariatric surgery, stomach capacity is approximately 30 milliliters. Sugared beverages are not well tolerated after bariatric surgery. It is recommended that 4 meals be consumed per day. Prolonged fasting periods may not be tolerated. 
Other Considerations  
Beta blockers or angiotensin converting enzyme ( ACE ) inhibitors could affect the blood 
flow to the liver, and therefore could affect the flow of the HepQuant SHUNT cholate 
test compounds into the liver as well.  If the flow of blood to the liver was altered by [CONTACT_476941], it could impact the SHUNT test results .  Additionally, because individual 
participants may take different amounts of these drugs, corrections for the different 
concentrations and their impact on blood flow to the liver cannot be made.  As such, participants who are currently taking either a be ta blocker or an ACE inhibitor will be 
asked to delay taking their normal morning dose the day of their testing and until the 90-minute test is completed.  Delaying these medications could cause a temporary 
elevation in blood pressure but the risk would be minimal, like that of participants that delay doses of medications in everyday life.  Participants will therefore be instructed to immediately take their morning dose after the final [ADDRESS_693201] Risk 
• Individuals with a history or suspected hypersensitivity to human serum albumin, or its preparations  will be excluded . 
• The HepQuant test has not been used on individuals who have undergone bariatric surgery.  Therefore, participants will be monitored closely.   If there are issues 
with tolerability, the test will be stopped and no additio nal tests will be attempted.  
In addition, the f ollowing procedures will be implemented:  
o The total volume of the oral cholate mixture will be 20 –[ADDRESS_693202] instances, there are no complications in obtaining a liver biopsy.   
Performing the  biopsy does introduce the risk of bleeding as well as a bile leak 
from the biopsy site .  It is also possible that inadvertent injury can occur to 
   
Current Version Dat e: 24OCT2019  IRBNet #:  1000376  
Previous Version Date: 05SEP  2019  Page 36 of 46 
Research Study protocol template version date 11/3/[ADDRESS_693203] Risk 
• Bleeding and bile leak risks are minimized by [CONTACT_533822], which allows for the physician to confirm adequate hemostasis and the absence of a bile leak.
 
• Inadvertent injury to the surrounding organs from the biopsy need are minimized by [CONTACT_533823] .
 
• A pathologist will review the results of the liver biopsy histology and the 
subsequent results and information will be available to the participant.  
Significant findings will be reported the bariatric surgeon .  The results from 
this biopsy will become part of the participant’s medical record.   
 
Stool Collection 
There  are no known risks with collecting stool.   
Protection Against Risk   
N/A 
MITIGATION OF RISKS  
Risk monitoring will be performed via  a weekly or biweekly individual review  of cases  
by [CONTACT_941] P rincipal Investigator, the study physician, and/or research coordinator, including 
progress or AEs occurring in the following: subject confidentiality, subject recruitment, 
informed consent process, data quality, and any external factors relevant for the safety of 
participants throughout the entire study.  In addition to these items, the study coordinator has been specifically  instruct ed to make the P rimary I nvestigator aware of all AEs , 
expected or unexpected  that arise during the course of the study.  Wound healing after 
invasive procedures (i.e., IV  line placement ) will be monitored .  Laboratory tests are 
obtained during the screening visits  of the study and any abnormal findings are sufficient 
to exclude individuals.  If an abnormal lab oratory value is obtained , the research 
participant  will be referred  to their primary care physician for follow-up.  If illness 
or injury occurs during a study procedure, participants will be transported to the Emergency Room if needed.   
Provisions to Protect the Privacy Interest of Subjects  
Participants  will be assigned unique identifiers for study -related records.  All precautions 
will be taken to make sure that only authorized individuals will access subject research records.  The collection of sensitive information about subjects will be limited to the minimum necessary to achieve the aims of the research, so that no unneeded sensitive information will be collected.    
   
Current Version Dat e: 24OCT2019  IRBNet #:  1000376  
Previous Version Date: 05SEP  2019  Page 37 of 46 
Research Study protocol template version date 11/3/2016  
 EARLY WITHDRAWAL OF SUBJECTS  
Investigator  Withdraw al of Subjects  
Participation in the study may also be discontinued at any time at the discretion of the 
Principal Investigator, without participant consent if:  
• The Principal Investigator [INVESTIGATOR_533783] a participant’s health or safety.  
• Participant has not followed study instructions. 
• Participant is not adherent to the intervention. 
• The TRI -MD has stopped the study. 
• Administrative reasons require a participant’s withdrawal . 
Participants will be withdrawn from the study if:  
• Participant uses any investigational ag ent (up to t he final study visit).  
• Female participant has become pregnant.  
Subject Request for Withdrawal from Study  
Participation in this study is voluntary.  Participants may decide not to participate in this study or may withdraw from this study at any time without penalty or loss of benefits.  If a participant leaves the study before the final regularly scheduled visit, he/she may be 
asked by [CONTACT_533824] a final visit for ‘end -of-study’ procedures.  This is to 
ensure there are no safety concerns.    
Data Collection and Follow -up for Withdrawn Subjects 
If the study is prematurely terminated, or if a subject request s withdrawal from the study, 
or if the Principal Investigator [INVESTIGATOR_533784] a subject  from the study , study dat a will be  
maintained in the research database up to the point of withdrawal.  This data will be included in subsequent analysis, as keepi[INVESTIGATOR_533785].   
ADVERSE EVENT REPORTING 
Adverse Events  
An AE i s defined as both an expected side effect that is of a serious nature, or an 
unexpected side effect/event regardless of severity.  Each participant is evaluated for AEs 
at every study visit.  Any event that is reported to the study staff and meets the criteria of an AE  will be documented as such and graded as to its attribution (unrelated to 
protocol, or possibly, probably, or definitely related to protocol) and severity (mild, 
moderate, or severe).  Any severe and/or unanticipated AE  will be reported to the 
institutional review board ( IRB) according to HRP 801 INVESTIGATOR GUIDANCE:  
Prompt Reporting Requirements.    
Recording and Notification of Adverse Events  
At each co ntact with the participant, the study team members will seek information on 
AEs by [CONTACT_5147], as appropriate, by [CONTACT_5148].  Information on all AEs 
   
Current Version Dat e: 24OCT2019  IRBNet #:  1000376  
Previous Version Date: 05SEP  2019  Page 38 of 46 
Research Study protocol template version date 11/3/2016  
 will be recorded immediately in the source document, and also in the appropriate AE  
module of the eCRF.  All clearly related signs, symptoms, and abnormal diagnostic 
procedures results will be recorded in the source document.    
Any event meeting the reporting guidelines per HRP 801 INVESTIGATOR GUIDANCE:  Prompt Reporting Requirements, will be reported to the AdventHealth Orlando IRB.    
Safety Monitoring Plan   
Safety Monitoring  
Adverse events will be documented and reported by [CONTACT_9137], the Principal Investigator, and other TRI- MD staff.  Research and safety data will be reviewed by [CONTACT_227559] I nvestigator .  This review will take place at regular meetings with the research 
coordinator and study physician where the safety labs for each new participant  will be 
reviewed.  Other items discussed will include progress or AEs  occurring in the following:  
subject confidentiality, subject recruitment, and the informed consent process.  All AEs 
and unexpected and/or severe AEs  will be reported to the AdventHealth  Orlando IRB per 
HRP 801 INVESTIGATOR GUIDANCE:  Prompt Reporting Req uirements .  The  TRI-
MD has a standing committee that meets monthly to review all AEs  in the clinical trials 
and will additionally be charged with review of the study.   
Data and Safety Monitoring Board (DSMB) or Equivalent  
Not applicable. 
ETHICAL CONSIDERATIONS  
Participation in this study is voluntary.  Participants  may decide not to participate in this study 
or may withdraw from this study at any time without penalty or loss of benefits.  No vulnerable populations will be studied in this protocol.    
Sharing of Results with Subjects  
Participants will be offered the opportunity to meet with the Principal Investigator [INVESTIGATOR_533786].  Copi[INVESTIGATOR_533787].  In addition, the Principal Investigator [INVESTIGATOR_533788]'s outcome to the participant, when available, if he or she requests the informat ion.   
FUNDING SOURCE  
This study will be externally funded by [CONTACT_3954].   
PARTICIPANT  STIPENDS OR PAYMENTS  
After the participant’s completion of all study visits, a total amount for the study will be $1,000-1,375.00. A Mastercard® payment will be processed with the Dollar amount per visits completed as indicated in the table below. Mastercard® payments may take up to 3 business days to be 
   
Current Version Dat e: 24OCT2019  IRBNet #:  1000376  
Previous Version Date: 05SEP  2019  Page 39 of 46 
Research Study protocol template version date 11/3/2016  
 processed, once requested. In the event the participant is unable to complete all study visits the 
payment will be prorated.  
 The payments are broken into two payments: Screening Visit 1  through Visit  5 (after completion  
of all visits through the 12 -week  time point ), and Visits 6 -7 (after completion of the remaining 
visits ending at the 52- week  time point). 
Compensation for Baseline Visit [ADDRESS_693204] is completed .  
Participants who agree to take part in this study will be paid for completed procedures according 
to the following schedule:    
Visit  Total  
Screening Visit  1 $50.00  
Screening Visit  2 
If both screening visits are combined, the payment will also be combined  $125.00  
Baseline  Visit  1   
Stool - $25.00 ; Dual cholate $50.00  $50.00 -125.00  
Baseline  Visit  2 $125.00  
Visit 3 (Surgery)  $150.00  
Visit 4  
Stool - $25.00 ; Dual cholate $50.00  $125.00-200.00  
Visit 5  
Stool - $25.00 ; Dual cholate $50.00  $125.00-200.00  
Visit 6  
Stool - $25.00 ; Dual cholate $50.00  $125.00-200.00  
Visit 7    
 Stool - $25.00 ; Dual cholate $50.00  $125.00-200.00  
TOTAL  $1,000 -1,375.00  
 
PUBLICATION PLAN 
TRI-MD faculty and staff will adhere to POLICY -TRI-ADM -005 (Access to Clinical Trial Data 
for Publication Purposes).   
   
Current Version Dat e: 24OCT2019  IRBNet #:  1000376  
Previous Version Date: 05SEP  2019  Page 40 of 46 
Research Study protocol template version date 11/3/2016  
 REFERENCES  
1. Ahmed MH, Abu EO, By[CONTACT_126469].  Non- alcoholic fatty liver disease (NAFLD): new challenge 
for general practitioners and important burden for health authorities?  Prim Care Diabetes. 
2010; 4(3):  129–37. 
2. Loomba R, Sanyal AJ. The global NAFLD epi[INVESTIGATOR_901] . Nat Rev Gastroenterol Hepatol . 
2013; 10(11): 686–90. 
3. Vernon G, Baranova A, Younossi ZM. Systematic review: the epi[INVESTIGATOR_533789]- alcoholic fatty liver disease and non -alcoholic steatohepatitis in adults.  
Aliment Pharmacol Ther . 2011; 34(3): 274–285. 
4. Sanyal AJ, Friedman SL, McCullough AJ, Dimick-Santos L. Challenges and opportunities in 
drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases–U.S. Food and Drug Administration Joint Workshop. Hepatology . 2015 ; 61(4): 1392–405. 
5. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science. 2011; 332(6037): 1519–1523 . 
6. Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterol ogy. 2005; 128(7): 1898–1906. 
7. Alkhouri N, McCullough AJ. Noninvasive diagnosis of NASH and liver fibrosis within the spectrum of NAFLD. Gastroenterol Hepatol (NY) . 2012; 8(10): 661–668. 
8. Papagianni M, Soforgianni A, Tziomalos K. Non- invasive methods for the  diagnosis of 
nonalcoholic fatty liver disease. World J Hepatol . 2015: 7(4): 638–648. 
9. Renelus B, Foster T. Noninvasive evaluation of nonalcoholic fatty liver disease. Clin Liver Dis. 2016; 7(3): 45–47. 
10. Dulai PS, Sirlin CB, Loomba R. MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice.  
J Hepatol . 2016; 65(5): 1006–1016. 
11. Hashemi SA, Alavian SM, Gholami- Fesharaki M. Assessment of transient elastography 
(FibroScan) for diagnosis of fibrosis in non -alcoholic fatty liver disease: A systematic review 
and meta- analysis.  Caspi[CONTACT_1629] J Intern Med. 2016; 7(4): 242–252. 
12. Barker KB, Palekar NA, Bowers SP, Goldberg JE, Pulcini JP, Harrison SA. Non -alcoholic 
steatohepati tis: effect of Roux -en-Y gastric by[CONTACT_4897]. Am J Gastroenterol.  2006; 
101(2): 368–373. 
13. Rabl C, Campos GM. The impact of bariatric surgery on nonalcoholic steatohepatitis. Semin Liver Dis. 2012; 32(1): 80–91. 
14. Hafeez S, Ahmed MH. Bariatric surgery as po tential treatment for nonalcoholic fatty liver 
disease: a future treatment by [CONTACT_533825]? J Obes. 2013; 839275: 1-11. 
15. Schneck A-S, Anty R, Patouraux S, et al. Roux- en Y gastric by[CONTACT_533826] -term 
remission of hepatocyte apoptosis and hepa tic histological features of non -alcoholic 
steatohepatitis. Front Physiol . 2016; 7: 344. 
   
Current Version Dat e: 24OCT2019  IRBNet #:  1000376  
Previous Version Date: 05SEP  2019  Page 41 of 46 
Research Study protocol template version date 11/3/2016  
 16. Alizai PH, Wendl J, Roeth AA, et al. Functional liver recovery after bariatric surgery —
a prospective cohort study with the LiMAx t est. Obes Surg. 2015; 25(11): 2047–2053. 
17. Barr J, Caballeria J, MArtinez -Arranz I, et al. Obesity -Dependent Metabolic Signatures 
Associated with Nonalcoholic Fatty Liver Disease Progression . J Proteome Res. 2012; 11: 
2521–2532. 
18. Crespo J, Martinez-Arranz I, Romero- Gómez M, et al. A non -invasive lipi[INVESTIGATOR_533790] -alcoholic steatohepatitis from steatosis: A blind validation 
study. J Hepatology. 2016; 64(2): S478. 
19. Nielsen MJ, Nedergaard AF, Sun S, et al. The neo- epi[INVESTIGATOR_120881] -C3 ELISA measures 
true formation of type III collagen associated with liver and muscle parameters. Am J Transl 
Res. 2013; 5(3): 303–315.  
20. Nielsen MJ, Veidal S, Karsdal M, Patel K. Plasma Pro -C3 (N- terminal type III collagen 
propeptide) predicts fibrosis progression in patients with chroni c hepatitis C . Liver Int . 2015; 
35: 429–437. 
21. Helmke S, Colmenero J, Everson GT. Noninvasive assessment of liver function. Curr Opin Gastroenterol. 2015; 31(3): 199–208. 
22. Schnabl B, Brenner DA. Interactkions between the intestinal microbiome and liver diseases. Gastroenterology . 2014; 146(6): 1513–1524. 
23. Bonder A, Afdhal N. Utilization of FibroScan in clinical practice. Curr Gastroenterol Rep . 
2014; 16(2): 372. 
24. Chen J, Talwalkar JA, Yin M, Glaser KJ, Sanderson SO, Ehman RL. Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by [CONTACT_533827]. Radiology . 2011; 259(3): 749–756. 
25. Dulai, P.S., C.B. Sirlin, and R. Loomba, MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical 
practice. Journal of Hepatology , 2016. 65(5): p. 1006-1016. 
26. Loomba, R., et al., Novel 3D Magnetic Resonance Elastography for the Noninvasive 
Diagnosis of Advanced Fibrosis in NAFLD: A Prospective Study. Am J Gastroenterol , 2016. 
111(7): p. 986-94. 
27. Costa -Silva, L., et al., MR elastography is effective for the non -invasive evaluation of 
fibrosis and necroinflammatory activity in patients with nonalcoholic fatty liver disease. European Journal of Radiology . 2018; 98: 82- 89. 
28. Lin, Z- H., et. al., Performa nce of the Aspartate Aminotransferase -to-Platelet Ratio Index for 
the Staging of Hepatitis C -Related Fibrosis: An Updated Meta-Analysis. Hepatology . 2011; 
53: 726-736. 
29. McPherson, S., et. al., Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis. Am J Gastroenterol . 2017; 112(5): 740-751. 
30. Thomas MS, Newman D, Leinhard OD, Karlsson, A. Test -retest reliability of automated 
whole body and compartmental muscle volume measurements on a wide bore 3T MR system . Eur Radiol . 2014; 24(9): 2279–2291. 
   
Current Version Dat e: 24OCT2019  IRBNet #:  1000376  
Previous Version Date: 05SEP  2019  Page 42 of 46 
Research Study protocol template version date 11/3/2016  
 31. Karlsson A, Rosander J, Romy T, et al. Automatic and quantitative assessment of regional 
muscle volume by [CONTACT_7163] -atlas segmentation using whole-body water–fat MRI. J Magn Reson 
Imaging. 2015; 41: 1558–1569. 
32. West J, Leinhard OD, Romu T, et al. Feasibility of MR -based body composition analysis in 
large scale population studies. PLoS ONE . 2016; 11(9): e0163332. 
33. Banerjee R, Pavlides M, Tunnicliffe EM, et al. Multiparametric magnetic resonance for the 
non-invasive diagnosis of liver disease.  J Hepatol . 2014; 60(1): 69–77. 
34. Pavlides M, Banerjee R, Sellwood J, et al. Multiparametric magnetic resonance imaging predicts clinical outcomes in patients with chronic liver disease.  J Hepatol . 2016; 64(2):  
308–315.  
   
 
Current Version Date:  24OCT2019  IRBNet #:  1000376  
Previous Version Date: 05SEP  2019  Page 43 of 46 
Research Study protocol template version date 11/3/[ADDRESS_693205]-Surgery  
Visit Number  SV1 SV2l BLV1m BLV2 V3 V4 V5 V6 V7 
Day a Varies  Varies  Varies  Varies  1 42 ±7  84 ±7  182 ±14  364 ±14  
Physical Exam  b  X X        
Provider time to explain study  X         
Assess participant e ligibility   X X   X     
Informed consent  c X         
Demography  c X         
AE/ConMed review    X X X  X X X X 
Drug Alcohol Tobacco 
Screen/ AUDIT questionnaire    X        
Height and body weight d X X X X X X X X X 
Body Mass Index (BMI)  X X X X X X X X X 
Vital signs  b X X X X X X X X X 
Screening Lab assessments  
(fasting)  e  X        
Urine pregnancy test  X X X X X X X X 
Urinalysis   X        
Urine drug screen   X        
HIV, HBV, HCV screen   X        
Hepatic panel   X X  X X X X 
Hemoglobin     X      
Pre-surgery diet f    X       
SoC Bariatric surgery      X     
Liver biopsy  g     X     
Blood collections for:  
OWL Metabolomics  
Nordic Bioscience    X X  X X X X 
Blood collections for:  
Biobanking h   X   X X X X 
Stool Collection   i   X   X X X X 
HepQuant SHUNT Dual Cholate 
Liver Diagnostic Kit j   X   X X X X 
IMAGING  
Fibro Scan®  X  X  X X X X 
MRIk  X  X  X X X X 
 
 
   
 
Current Version Date:  24OCT2019  IRBNet #:  1000376  
Previous Version Date: 05SEP  2019  Page 44 of 46 
Research Study protocol template version date 11/3/2016  
  
SCHEDULE OF EVENTS, cont.  
Abbreviations:  AE  = adverse event ; AUDIT  = Alcohol Use Disorders Identification Test; CH = Celebration Health; ConMed = concomitant medication; HBV = hepatitis B virus; 
HCV = hepatitis  C virus; HIV = human immunodeficiency virus; MRE  = magnetic resonance elastography; MRI = magnetic resonance imaging; SoC = standard of care; 
TRI-MD = Translational Research Institute for Metabolism and Diabetes.   
Note:  Screening Visit 1  (SV1) may occur either at CH  or TRI -MD. Surgery (V3) occurs at CH. All other visits and procedures, including the combination screening visit 
(if applicable), occur at TRI -MD.  
a. Pre-surgery time points will vary based upon insurance requirements, length of diet, and other clinical needs.    
b. Performed by [CONTACT_533828] a part of standard of care procedures  at SV1 and at TRI-MD at indicated visits per our standard research procedures .   
c. Performed by [CONTACT_533829]/CH provider.    
d. Height measured at SV1  and SV2  only; weight measured at designated visits for calculation of body mass index (BMI).   
e. Screening laboratory assessment  are collected at SV2 or the combination SV1/SV2 visit and  include:  complete blood count (CBC ), platelet count, comprehensive metabolic 
panel (CMP), lipid panel , prothrombin (may include prothrombin time [PT ]/international n ormalized ratio [INR ]/partial thromboplastin time [PTT ]), activated partial 
thromboplastin time (APTT), , hemoglobin A1c ( HbA1 c), thyroid stimulating hormone (TSH) with reflex to thyroxine ( T4), parathyroid hormone (PTH).   
f. The pre -surgery diet varies and occurs as per standard of care.   BLV [ADDRESS_693206] 5 days of the liquid diet.    
g. Liver biopsy for clinical histology and research.  Participants without non-alcoholic steatohepatitis (NASH) upon biopsy will not continue longitudinal assessment . The Liver 
Biopsy is the final criteria determining the cohort (NASH vs NON -NASH)  
h. Blood collections for biobanking:  plasma, serum, PAX  DNA, P800 tube .  
i. Stool will be collected during clinic visit if possible. If not, a home stool collection kit will be sent home with participant.   
j. HepQuant SHUNT Dual Cholate Liver Diagnostic will be discontinued if there are any feasibility or tolerability issues.    
k. The TRI-MD liver fat percentage by [CONTACT_533830] (PDFF) will be used to ascertain eligibility. For participants that meet eligibility criteria at SV2, data will be 
sent to Perspectum and AMRA to generate PDFF and other liver endpoints  from MRI da ta collected at SV2 and BLV 2, V4, V 5, V6 and V7.  
l. SV2 will occur as soon as possible after SV1.  
m. BLV1 will occur within a maximum of 28 days from SV2. 
 
 
 
 
 
 
 
  
 
   
 
Current Version Date:  24OCT2019  IRBNet #:  1000376  
Previous Version Date: 05SEP  [ADDRESS_693207]  
(AUDIT ) QUESTIONNAIRE  
 

   
 
Current Version Date:  24OCT2019  IRBNet #:  1000376  
Previous Version Date: 05SEP  [ADDRESS_693208] to Platelet Ratio (APRI) score is calculated via the following formula:   (AST in IU/L) / (AST Uppe r Limit of Normal in IU/L) / (Platelets in 10
9/L) 
 The Fibrosis- 4 (FIB -4) Index for Liver Fibrosis is calculated with the following formula:  
(Age x AST) / (Platelets x √(ALT))  
 